🇺🇸 FDA
Patent

US 10934274

Quinoline derivatives as TAM RTK inhibitors

granted A61KA61K31/4709A61K31/497

Quick answer

US patent 10934274 (Quinoline derivatives as TAM RTK inhibitors) held by Lead Discovery Center GmbH expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Lead Discovery Center GmbH
Grant date
Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/4709, A61K31/497, A61K31/501, A61K31/506